CN108069985B - 3-O-demethyl-4-N-acetyl staurosporine and preparation method and application thereof - Google Patents
3-O-demethyl-4-N-acetyl staurosporine and preparation method and application thereof Download PDFInfo
- Publication number
- CN108069985B CN108069985B CN201810016286.0A CN201810016286A CN108069985B CN 108069985 B CN108069985 B CN 108069985B CN 201810016286 A CN201810016286 A CN 201810016286A CN 108069985 B CN108069985 B CN 108069985B
- Authority
- CN
- China
- Prior art keywords
- staurosporine
- separation
- culture
- acetyl
- rice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a 3-O-demethyl-4-N-acetyl staurosporine and a preparation method and application thereof, the compound has antitumor activity and protein kinase inhibition effect, and can be used for preparing protein kinase inhibitor drugs and antitumor drugs. The preparation method is characterized in that the rice fermentation method is used for preparing the rice from fermentation products of actinomycetes sp.CICC 11026, the fermentation products are extracted by ethyl acetate and then separated and purified by gel chromatography and high performance preparative liquid chromatography, and the operation and the implementation are easy.
Description
Technical Field
The invention relates to the technical field of compounds prepared by culturing actinomycetes, and particularly relates to 3-O-demethyl-4-N-acetyl staurosporine with antitumor activity, and a preparation method and application thereof.
Background
Staurosporine (STA), an indolocarbazole alkaloid isolated earlier than 1977 from the culture medium of actinomycetes in soil, has been shown to have various pharmacological activities such as antitumor activity, antibacterial action, inhibition of platelet aggregation, and the like, since then. Most importantly, it has a broad spectrum of protein kinase inhibitory activity, such as on protein kinase c (pkc), tyrosine kinase (TPK), cell cycle dependent kinase proteins, and the like. But further research on the protein kinase is limited due to poor selectivity of the protein kinase. The derivatives discovered later exhibit certain antitumor and protein kinase inhibitory activities, and have entered clinical trials. For example, the natural source staurosporine derivative UCN-01 has completed the clinical phase II test for treating metastatic pancreatic cancer by combining with fluorodioxypyrimidine, and the semi-synthesized derivative Midostaurin has made a major breakthrough in the clinical research for treating FTL3 mutant Acute Myelogenous Leukemia (AML) and has been successfully marketed. The synthetic staurosporine analog CEP-2563 has been completed in phase i clinical studies for the treatment of solid tumors and Enzastaurin, a selective protein kinase beta (PKC β) inhibitor, is in phase iii clinical studies for the treatment of lymphomas. From the perspective of the staurosporine derivatives which have entered clinical tests, the compounds still have the prospect of further development, the staurosporine derivatives are excavated, and the protein kinase inhibitor with better selectivity is screened out, so that the protein kinase inhibitor has important social and economic significance for the research and development of new drugs for resisting tumors such as acute myelogenous leukemia, colon cancer, non-small cell lung cancer, liver cancer and the like, and tumor diseases related to kinases, immune diseases such as systemic lupus erythematosus, eye diseases such as glaucoma, and neurodegenerative diseases such as Alzheimer and the like.
Disclosure of Invention
The invention provides 3-O-demethyl-4-N-acetyl staurosporine and a preparation method and application thereof, wherein the 3-O-demethyl-4-N-acetyl staurosporine is prepared from a fermentation product of actinomycete Streptomyces sp.CICC 11026 by a rice fermentation method, and the compound has antitumor activity and protein kinase inhibition effect and can be used for preparing protein kinase inhibitor medicines and antitumor medicines.
3-O-demethyl-4-N-acetyl staurosporine having the structure of formula I:
the invention provides a preparation method of 3-O-demethyl-4-N-acetyl staurosporine with anti-tumor activity, which is prepared by fermenting rice with actinomycete Streptomyces sp.CICC 11026 and separating and purifying, and is easy to operate and implement.
A process for the preparation of 3-O-desmethyl-4-N-acetyl staurosporine comprising the steps of:
1) inoculating Streptomyces sp.CICC 11026 into a Gao's I liquid culture medium, and performing shake culture to obtain a fermentation culture medium inoculated with actinomycetes;
2) inoculating the fermentation medium inoculated with the actinomycetes in the step 1) into a rice fermentation medium, and standing for culture to obtain a solid fermentation product;
3) separating and purifying the solid fermentation product to obtain the 3-O-demethyl-4-N-acetyl staurosporine.
In the step 1), actinomycete Streptomyces sp.CICC 11026 adopts a strain sold in China center for Industrial culture Collection of microorganisms (CICC), the number of the strain is 11026, and the strain is selected and purchased from a website: http:// www.china-cic.
The conditions of shake culture are as follows: shaking culture at 20-35 deg.c and 100-300 rpm for 2-5 days; further, the conditions of shake culture are as follows: shaking culture is carried out for 3-4 days at the temperature of 25-30 ℃ and the rpm of 150-210 rpm.
In the step 2), the rice fermentation medium consists of rice, water and sea salt, and the ratio of the rice to the water to the sea salt is as follows: 40 g: 40 mL-80 mL: 0.5g to 3 g.
The static culture conditions are as follows: standing and culturing for 60-80 days at 23-33 ℃; further, the conditions of the static culture are as follows: and (3) standing and culturing for 68-73 days at 25-30 ℃.
In step 3), the separation and purification comprises: extracting the solid fermentation product with ethyl acetate, concentrating the extract, and performing normal pressure gel chromatography coarse separation to obtain a mixed component; and (3) separating the mixed components by medium-pressure preparation liquid phase separation and high-performance preparation liquid phase chromatography separation and purification to obtain the compound with the structure shown in the formula I.
The conditions of the crude separation by the normal pressure gel chromatography are as follows: the adopted filler is hydroxypropyl sephadex (LH-20), the adopted eluent is a methanol-water system with the volume percentage of 20-100%, and the methanol-water system with the volume percentage of 20% is that the volume ratio of methanol to water is 20: 80, the volume percentage of the 100% methanol-water system is that the volume ratio of methanol to water is 100: 0;
the conditions for the separation of the medium-pressure preparation liquid phase are as follows: the adopted filler is octadecylsilane chemically bonded silica, the adopted mobile phase is methanol-water solution with the volume percentage of 40-100%, and the methanol-water solution with the volume percentage of 40% is methanol and water with the volume ratio of 40: 60, volume percent 100% methanol-water solution is methanol and water in a 100 volume ratio: 0;
the conditions of the high performance preparative liquid chromatography separation and purification are as follows: the adopted filler is octadecylsilane chemically bonded silica, the adopted mobile phase is acetonitrile-water solution with the volume percentage of 40-48%, and the acetonitrile-water solution with the volume percentage of 40% refers to that the volume ratio of acetonitrile to water is 40: 60, volume percent 48% acetonitrile-water solution means that the volume ratio of acetonitrile to water is 48: 52.
the activity evaluation test of the structure of the invention adopting the human prostate cancer cell strain PC3 shows stronger cytotoxicity, and the structure of the invention also shows inhibition activity in a kinase inhibition test. The compound with the structure shown in the formula I can be used for preparing protein kinase inhibitor medicines and antitumor medicines. The compound provided by the invention can be used for preparing medicines for treating diseases such as leukemia, breast cancer, pancreatic cancer and the like related to excessive or abnormal cell proliferation, and has important social and economic significance in the research and development of new medicines for treating kinase-related neurogenic diseases such as Alzheimer and Huntington, immune system diseases such as systemic lupus erythematosus and the like
Compared with the prior art, the invention has the following advantages:
the structure shown in the formula I has good protein kinase inhibition activity, particularly shows strong antitumor activity, and has important application value in the antitumor aspect, such as treatment of acute myeloid leukemia, non-small cell lung cancer, liver cancer, kidney cancer, thyroid cancer, pancreatic cancer, ovarian cancer, breast cancer and the like. The method can also be applied to the development of new drugs for protein kinase related neurodegenerative diseases such as Alzheimer and Huntington, eye diseases such as glaucoma and senile maculopathy.
Detailed Description
Example 1
Fermentation of compounds
The actinomycetes adopt Streptomyces sp.CICC 11026 sold by China industrial microorganism strain preservation management center;
1) inoculating actinomycete Streptomyces sp.CICC 11026 into a 500mL conical flask, wherein each flask contains 250mL of a Gao's I liquid culture medium, and culturing for 3 days in a shaking table with the culture condition of 28 ℃ and 180rpm to obtain seed liquid capable of being fermented and cultured;
2) inoculating the seed solution obtained in the step 1) to a rice culture medium (rice culture medium, which is prepared from the following components: 40g of rice, 60mL of water and 1.5g of sea salt), the inoculation volume is 12mL, the culture condition is constant temperature and static culture for 70 days at 28 ℃, and a solid fermentation product containing the compound with the anti-tumor activity is obtained.
Preparation and identification of compounds
Soaking and extracting a solid fermentation product containing the compound with the antitumor activity for 3 times by using ethyl acetate, recovering and concentrating a solvent, performing normal-pressure gel chromatography (the adopted filler is hydroxypropyl sephadex LH-20) on the obtained ethyl acetate part for crude separation, performing gradient elution by using a methanol-water system with the volume percentage of 20-100%, wherein the volume of each 1/4 column is one fraction, and performing TLC analysis to combine fractions containing the target compound. Separating the target components by medium pressure preparative chromatography (Sepax ethyl C-18(10 μm,30 × 400mm) chromatographic column with detection wavelength of 295nm), eluting with methanol-water solution with volume percentage of 40% -100% in a gradient of 10mL/min, and mixing fractions containing the compound by TLC analysis.
The obtained fraction containing the compound is separated by adopting high performance preparative liquid chromatography (Agilent Pursuit C-18(10 mu m,21.2 multiplied by 250mm) chromatographic column, the detection wavelength is 292nm), the adopted mobile phase is an acetonitrile/water system with the volume percentage of 40 percent to 48 percent (40min) and is eluted by a gradient of 10mL/min, the chromatographic peak of 20 min to 21min is collected, the solvent is recovered, and the compound A61-31A is obtained, and the structure of the compound is shown as the structure in the formula I. MoleculeThe formula is calculated as C according to high resolution mass spectrum HR-ESI-MS28H24N4O4(m/z＝[M+H]+481.1866, calculated 481.1876), the nuclear magnetic data are shown in table 1, thus identifying the compound as (3 '-O-methyl-4' -N-methyl-4 '-acetyl-4' -epi-staurosporine), named a61-31A, and the specific structure is as follows:
TABLE 11H 600MHz,13C 125MHz(CD3OD)
Experiment of antitumor Activity
IC for determining human prostate cancer cell strain PC3 cells50And (5) carrying out experiments. Using SBR cell experiment, taking cells in logarithmic growth phase, 1 × 105one/mL in 96-well plate, CO2Culturing for 24 hr in incubator, taking out culture plate, adding samples to be tested with different concentrations into each well, adding the drug, mixing the culture plate with the micro-porous plate oscillator, and placing in CO2The cultivation was continued in the incubator for 48 hours. The plate was removed, 50. mu.l of pre-cooled 50% trichloroacetic acid (TCA) was gently added to each well of the surface of the medium to fix it, and after standing for 5 minutes, the plate was moved to 4 ℃ and left to stand for 1 hour. Pouring out the fixing liquid, washing each hole with deionized water for 5 times, spin-drying, and air-drying. Mu.l of SRB solution was added to each well, left at 25 ℃ for 10 minutes, the supernatant removed, washed 5 times with 1% by volume acetic acid, air dried, and the bound SRB dissolved with 150. mu.l of 10mmol/L unbuffered Tris base (pH10.5) with shaking. And (4) placing the plate in a microplate reader to measure the light absorption of each hole, wherein the measurement wavelength is 540 nm. Calculating the inhibition rate of the drug on cell proliferation according to the OD value of each well, and calculating the half inhibition concentration IC by using a Logit method according to the inhibition rate of each concentration50。
TABLE 2
| Compound (I) | IC50(μM) |
| A61-31A | 0.16 |
Inhibition activity of protein kinase
By usingKinEASETMTK assay kit (Cisbio), protein kinase inhibitory activity of the obtained compounds at various concentrations was determined with Staurosporine (STU) positive drug. HRFT value is obtained by measuring the ratio of fluorescence of protein kinase at 665nm and 620nm after excitation with 340nm ultraviolet light, i.e. HTRF value T ═ F665nm/F620nm]×104. Protein kinase (PKC- α, ROCK 2)% inhibition ═ ((T test) - (Tmin))/((Tmax) - (Tmin)) × 100, Tmax is the HTRF value of the reaction solution, and Tmin is the HTRF value of the blank reaction solution without protein kinase. Finally calculating half inhibition concentration IC according to each concentration inhibition rate50As shown in table 3:
TABLE 3
As can be seen from Table 2, the activity evaluation test using the human prostate cancer cell line PC3 shows good inhibitory activity, wherein formula I shows strong cytotoxicity. As can be seen from Table 3, the structure of formula I of the present invention shows good protein kinase inhibitory activity. The compound with the structure shown in the formula I has huge application potential in resisting tumor and kinase-related neurological diseases such as senile dementia, vision-related diseases such as glaucoma, senile maculopathy and the like, and can be applied to preparing protein kinase-related small-molecule inhibitor medicines and antitumor medicines.
Claims (2)
1. A method for preparing 3-O-demethyl-4-N-acetyl staurosporine, comprising the steps of:
1) inoculating Streptomyces sp.CICC 11026 into a Gao's I liquid culture medium, and performing shake culture to obtain a fermentation culture medium inoculated with actinomycetes;
the conditions of shake culture are as follows: shaking-culturing at 25-30 ℃ and 150-210 rpm for 3-4 days;
2) inoculating the fermentation medium inoculated with the actinomycetes in the step 1) into a rice fermentation medium, and standing for culture to obtain a solid fermentation product;
the static culture conditions are as follows: standing and culturing for 68-73 days at 25-30 ℃;
3) separating and purifying the solid fermentation product to obtain 3-O-demethyl-4-N-acetyl staurosporine;
the separation and purification comprises the following steps: extracting the solid fermentation product with ethyl acetate, concentrating the extract, and performing normal pressure gel chromatography coarse separation to obtain a mixed component; separating the mixed components by medium-pressure preparative liquid phase separation and high-performance preparative liquid chromatography to obtain 3-O-demethyl-4-N-acetyl staurosporine with the structure of formula I;
the conditions of the crude separation by the normal pressure gel chromatography are as follows: the adopted filler is hydroxypropyl sephadex, and the adopted eluent is a methanol-water system with the volume percentage of 20-100%;
the conditions for the separation of the medium-pressure preparation liquid phase are as follows: the adopted filler is octadecylsilane chemically bonded silica, and the adopted mobile phase is methanol-water solution with volume percentage of 40-100%;
the conditions of the high performance preparative liquid chromatography separation and purification are as follows: the adopted filler is octadecylsilane chemically bonded silica, and the adopted mobile phase is acetonitrile-water solution with volume percentage of 40-48%;
2. the method of claim 1, wherein the rice fermentation medium of step 2) comprises rice, water and sea salt, and the ratio of rice to water to sea salt is: 40 g: 40 mL-80 mL: 0.5g to 3 g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810016286.0A CN108069985B (en) | 2018-01-08 | 2018-01-08 | 3-O-demethyl-4-N-acetyl staurosporine and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810016286.0A CN108069985B (en) | 2018-01-08 | 2018-01-08 | 3-O-demethyl-4-N-acetyl staurosporine and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108069985A CN108069985A (en) | 2018-05-25 |
| CN108069985B true CN108069985B (en) | 2019-12-31 |
Family
ID=62156511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810016286.0A Active CN108069985B (en) | 2018-01-08 | 2018-01-08 | 3-O-demethyl-4-N-acetyl staurosporine and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108069985B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111303164B (en) * | 2019-09-19 | 2021-03-23 | 杭州科兴生物化工有限公司 | Staurosporine derivatives and preparation method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106831898B (en) * | 2016-12-27 | 2019-06-18 | 杭州科兴生物化工有限公司 | Compound and its preparation method and application with protein kinase inhibiting activity |
| CN107417751B (en) * | 2017-06-15 | 2019-11-22 | 杭州科兴生物化工有限公司 | Indole carbazole compound and its preparation method and application |
| CN107400137B (en) * | 2017-06-15 | 2019-10-15 | 杭州科兴生物化工有限公司 | Compound with anti-tumor activity and its preparation method and application |
| CN107417743B (en) * | 2017-06-15 | 2020-07-21 | 杭州科兴生物化工有限公司 | Staurosporine aldehyde group substituted derivative and preparation method and application thereof |
-
2018
- 2018-01-08 CN CN201810016286.0A patent/CN108069985B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108069985A (en) | 2018-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106831898B (en) | Compound and its preparation method and application with protein kinase inhibiting activity | |
| CN107417751B (en) | Indole carbazole compound and its preparation method and application | |
| CN108299467B (en) | Indolocarbazole alkaloid with cytotoxic activity, preparation method and application thereof | |
| CN108069985B (en) | 3-O-demethyl-4-N-acetyl staurosporine and preparation method and application thereof | |
| CN107417743B (en) | Staurosporine aldehyde group substituted derivative and preparation method and application thereof | |
| CN107569491A (en) | A kind of application of staurosporine class compound | |
| CN108329326B (en) | Indolocarbazole alkaloid derivative and preparation method and application thereof | |
| CN108084205B (en) | A kind of indole carbazole Alkaloid and its preparation method and application | |
| CN107446011A (en) | A kind of staurosporine class compound and its preparation method and application | |
| CN107556323B (en) | A kind of amino replaces staurosporine class compound and its preparation method and application | |
| CN111303164B (en) | Staurosporine derivatives and preparation method and application thereof | |
| CN112125918B (en) | Aromatic polyketone compounds Talarogyoxanones A and B as well as preparation method and application thereof | |
| CN107325142A (en) | A kind of staurosporine class compound and its preparation method and application | |
| CN111808088B (en) | Compounds tersaphilone B and E, preparation method thereof and application thereof in preparing antitumor drugs | |
| CN109020991B (en) | Medadamycin compounds and preparation method and application thereof | |
| CN107674105B (en) | Indole carbazole compound and preparation method and application thereof | |
| CN108164537A (en) | A kind of staurosporine analog derivative of 3 substitutions and its preparation method and application | |
| CN112300155A (en) | Preparation method and application of anti-senile dementia compound from ocean | |
| CN111909021A (en) | Sorbicillinoids compound and preparation method and application thereof | |
| CN108164538B (en) | The indole carbazole compound and its preparation method and application that N-13 tyrosine derivative replaces | |
| CN110746446A (en) | Dimeric tetrahydro xanthene compound and preparation method and application thereof | |
| CN108383889A (en) | Open loop staurosporine derivative and its preparation method and application | |
| CN116874417B (en) | Pyridine alkaloid and application thereof in preparation of antitumor drugs | |
| CN115160236B (en) | Corallorazines compound and preparation method and application thereof | |
| CN107903277B (en) | Mould chlorins compound of a kind of N- methyl-Mei Da and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20220223 Address after: 311400 No. 1, No. 13 Road, Dongzhou industrial functional zone, Dongzhou street, Fuyang District, Hangzhou City, Zhejiang Province Patentee after: Zhejiang Meixin Holding Co.,Ltd. Address before: 311401 No. 1, No. 13 Road, Dongzhou industrial functional zone, Fuyang District, Hangzhou City, Zhejiang Province Patentee before: HANGZHOU KEXING BIOCHEM Co.,Ltd. |
|
| TR01 | Transfer of patent right |